Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort

This multicentered US cohort study demonstrates that the majority of patients receiving TNF antagonists would not meet trial eligibility criteria and achieve lower clinical responses. These findings highlight the tradeoff between defining treatment responsive populations and achieving results that can be generalized for broader patient populations.